Avidicure
avidicure.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$50M
1 round on record
Latest round
$50M
Seed · May 2025 · 16 mo ago
Backers
3
BioGeneration Ventures, Kurma Partners
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 2, 2025
Raised a round Seed $50M · led by EQT Life Sciences · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | May 2025 | $50M | EQT Life Sciences lead, Kurma Partne | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Kurma Partners 
V-Bio Ventures Similar startupsby what they do, their industry and backers
Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular…
Bioarchitech develops multifunctional immunotherapies targeting cancer and virus-related diseases, including innovative viral and RNA-based…
Draupnir Bio is developing new innovative therapies for patients.
OncoHealth – Beyond the Diagnosis. We focus on the complexities of cancer so you can focus on the care.
TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its…
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Overview
Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer.
News
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer patient samplesAMSTERDAM, May 22, 2025 (GLOBE NEWSWIRE) -- Avidicure
Read more
Report
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer patient samplesAMSTERDAM
Read more
Report
Avidicure boosting immune activation with $50M seed round
Newco Avidicure NV arrived on the scene with a hefty $50 million in seed funding to advance novel antibody formats the company says will surpass the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and antibody-drug co
Read more
Report
Avidicure: $50 Million Seed Funding Closed For Developing New Multifunctional Antibody Modality
Avidicure, a biotechnology company creating an entirely new multifunctional antibody modality with broad applicability in oncology, announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partne
Read more
Report
Financials
Total raised
$50M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2025 | $50M | Details |